Schattner A, Miller K B, Kaburaki Y, Schwartz R S
Clin Immunol Immunopathol. 1986 Dec;41(3):417-26. doi: 10.1016/0090-1229(86)90012-7.
Sixteen-six (16/6) is a major cross-reactive idiotype of monoclonal anti-DNA antibodies, which was derived from the fusion of lymphocytes of a patient with systemic lupus erythematosus (SLE). Antibodies with the 16/6 idiotype (16/6 Id) are increased in the sera of patients with SLE and deposited in their gomeruli and skin. Since stimulated lymphocytes from healthy persons have the capacity to produce 16/6 Id, the mechanisms controlling its expression in health and their possible failure in SLE are of considerable interest. A defect in suppressor cell function was found in a high proportion of patients with SLE and in some of their first-degree relatives. Suppressor cell function in 15 SLE patients and in 53 relatives was compared with the level of 16/6 Id as well as with immunoglobulin levels and anti-DNA antibodies. Ten of 15 SLE patients and 26 of 53 first-degree relatives had increased serum 16/6 levels, which was found in only 1 of 35 healthy controls and household members. Of the 10 SLE patients with increased 16/6, six had a suppressor cell defect (P less than 0.1). Among the 26 first-degree relatives with elevated 16/6 Id levels, 12 had associated suppressor defect and in only two cases was a suppressor cell defect unaccompanied by increased 16/6 (P less than 0.005). For the group of 18 patients and relatives showing concomitant suppressor cell defect and increased 16/6, a correlation was found between the severity of the suppressor cell defect and the level of 16/6 Id in the serum. The increased 16/6 in the relatives was not associated with hypergammaglobulinemia or with measurable anti-DNA activity in the serum. We conclude that the suppressor cell defect in relatives of SLE patients is often associated with increased expression of antibodies with the 16/6 idiotype. However, additional mechanisms are involved in the regulation of 16/6 Id and the development of clinical SLE, since increased 16/6 was commonly found in the presence of a normal suppressor T-cell function.
16/6是单克隆抗DNA抗体的一种主要交叉反应独特型,它源自一名系统性红斑狼疮(SLE)患者淋巴细胞的融合。具有16/6独特型(16/6 Id)的抗体在SLE患者血清中增多,并沉积于其肾小球和皮肤中。由于健康人的受刺激淋巴细胞有产生16/6 Id的能力,因此控制其在健康状态下表达的机制以及它们在SLE中可能出现的功能失调备受关注。在高比例的SLE患者及其一些一级亲属中发现了抑制细胞功能缺陷。将15例SLE患者和53名亲属的抑制细胞功能与16/6 Id水平以及免疫球蛋白水平和抗DNA抗体进行了比较。15例SLE患者中有10例,53名一级亲属中有26例血清16/6水平升高,而在35名健康对照者和家庭成员中仅有1例出现这种情况。在10例16/6升高的SLE患者中,6例存在抑制细胞缺陷(P小于0.1)。在26例16/6 Id水平升高的一级亲属中,12例伴有抑制缺陷,只有2例抑制细胞缺陷而无16/6升高(P小于0.005)。对于18例同时出现抑制细胞缺陷和16/6升高的患者及亲属,发现抑制细胞缺陷的严重程度与血清中16/6 Id水平之间存在相关性。亲属中16/6升高与高球蛋白血症或血清中可检测到的抗DNA活性无关。我们得出结论,SLE患者亲属中的抑制细胞缺陷常与具有16/6独特型抗体的表达增加有关。然而,16/6 Id的调节和临床SLE发展还涉及其他机制,因为在抑制性T细胞功能正常的情况下也常见16/6升高。